Psilocybin-assisted therapy has been identified as a potential treatment in healthcare and has shown success in treating patients diagnosed with obsessive-compulsive disorder (Ehrmann et al., 2021; Moreno et al., 2006), major depressive disorder (Carhart-
Simounet, Madison, Drinnon, Joy
core +1 more source
Exploring the relationship between personality traits, attitudes toward psilocybin use, and motivations for using psilocybin [PDF]
Background: Psilocybin use is gaining popularity in research alongside evolving legal perspectives and liberal attitudes toward substance use. Despite this, little research has examined the individual factors driving psilocybin use.
Mifsud, Molly, Robinson, Jill
core
Apomorphine and psilocybin to improve recovery from coma in the intensive care unit: protocol for a prospective, open-label, dose-escalation study. [PDF]
BMJ OpenEigenbrodt AK +7 more
europepmc +1 more source
Matters arising: Methodological concerns and interpretative limitations of assessing subjective effects of ketamine. [PDF]
Npj Ment Health ResJanavičius R.
europepmc +1 more source
A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults. [PDF]
Pharmaceuticals (Basel)Levy-Cooperman N +7 more
europepmc +1 more source
Psilocybin enhances sociability only in altered behavioural state and does not need an awake experience to be effective. [PDF]
Nat CommunSong C, Chang T, Buchborn T, Knöpfel T.
europepmc +1 more source
Reply to 'Methodological concerns and interpretative limitations of assessing subjective effects of ketamine'. [PDF]
Npj Ment Health ResDahan JDC +3 more
europepmc +1 more source
Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD. [PDF]
Front PsychiatryShnayder S +7 more
europepmc +1 more source